rs6849729 — SLC2A9

Intronic SLC2A9 variant 70 bp from rs6815001 tagging the same renal urate-clearance haplotype; the T allele is associated with reduced urate excretion and elevated serum uric acid, while the C allele tags the protective haplotype that supports more efficient renal urate clearance

See your personal result for SLC2A9

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SLC2A9 rs6849729 — Tagging the Renal Urate-Clearance Haplotype

The SLC2A9 gene encodes GLUT911 GLUT9
Glucose Transporter 9 — despite its name, GLUT9 transports urate 45–60 times faster than glucose in the kidney proximal tubule; it is the dominant transporter for urate reabsorption back into the bloodstream, the largest known genetic determinant of serum uric acid levels in humans. Genetic variants across the SLC2A9 locus account for more of the variance in serum urate than any other single genomic region — more than dietary purines, more than alcohol, more than body weight alone in population studies.

rs6849729 sits in an intron of SLC2A9 at GRCh38 position chr4:9,957,108, just 70 base pairs from the neighboring intronic variant rs6815001 (9,957,038). The two variants share a nearly identical population frequency profile — strongly suggesting they are in tight [linkage disequilibrium | LD — the tendency for nearby variants to be inherited together, such that knowing one tells you a great deal about the other], and both tag the same regulatory haplotype associated with reduced renal urate excretion. The T allele of rs6849729 and the G allele of rs6815001 travel together on the same chromosome copies in most populations.

The Mechanism

GLUT9 exists in two isoforms. The long form (GLUT9a) sits on the basolateral membrane of proximal tubule cells and reabsorbs urate from the interstitium back into the blood. The short form (GLUT9b) on the apical membrane handles urate secretion into the tubular lumen. The balance between these two activities — how much urate the kidney retains versus releases — determines your steady-state serum uric acid level.

Intronic variants like rs6849729 do not change the amino acid sequence of GLUT9. Their effect is regulatory: they alter transcription factor binding, modify the balance of GLUT9a versus GLUT9b expression, or shift splice-site efficiency. Fine-mapping of the SLC2A9 4p16.1 region22 Fine-mapping of the SLC2A9 4p16.1 region
Wei et al. 2014 — identified five independent marginal effects and three epistatic SNP pairs at SLC2A9, establishing that multiple haplotype blocks in this intronic region independently regulate renal urate clearance has confirmed at least five statistically separable effects in this vicinity, and rs6849729 tags one of these blocks.

The T allele at rs6849729 is most frequent in East Asians (~91%), who have the highest gout prevalence globally, and least frequent in people of African ancestry (~33%), where gout has historically been less prevalent. This population frequency gradient — mirroring the pattern observed across multiple SLC2A9 intronic risk variants — strongly suggests the T allele tags a haplotype associated with reduced net urate clearance.

The Evidence

SLC2A9 as the dominant urate locus: Independent GWAS in 2008 established the SLC2A9 intronic region as the strongest known genetic signal for serum uric acid. Vitart et al.33 Vitart et al. identified variants in introns 4 and 6 of SLC2A9 explaining 1.7–5.3% of serum urate variance in combined Croatian, UK, and German cohorts. At the same time, Döring et al.44 Döring et al. replicated the signal in KORA and confirmed a pronounced sex-specific effect: SLC2A9 intronic variants explain 6% of urate variance in women but only 1.2% in men, with the difference attributed to estrogen's independent uricosuric (urate-excreting) action on the kidney.

Genomic neighbourhood fine-mapping: Wei et al. (2014)55 Wei et al. (2014) performed conditional analysis of 4p16.1 and found five independent marginal effects and three epistatic SNP pairs in the SLC2A9 region, together explaining 1.5% more urate variance than the lead SNP alone. rs6849729 is situated within this fine-mapped intronic region and shares a population frequency profile consistent with other risk-haplotype tag SNPs at this locus, but has not been the subject of an independent, published GWAS result to date. The evidence for its specific effect is therefore inferred from locus architecture and LD pattern rather than directly cited.

Sex-specific amplification across all SLC2A9 signals: Dalbeth et al. (2015)66 Dalbeth et al. (2015) reviewed SLC2A9 genetic architecture across multiple ethnicities and confirmed that sex-specific amplification — 3.4–8.8% variance explained in women versus 0.5–2.0% in men — is a consistent feature of SLC2A9 intronic variants rather than specific to any single tag SNP. Post-menopausal women, who lose estrogen's independent uricosuric buffering, are the most vulnerable subgroup for any SLC2A9 risk haplotype.

Multiple independent SLC2A9 signals: Chen et al. (2020)77 Chen et al. (2020) applied conditional analysis in African-ancestry cohorts and identified a second independent signal at SLC2A9 reaching p = 5.75 × 10⁻¹⁷ after conditioning on the primary variant, confirming that the SLC2A9 locus contains multiple causal or tagging variants acting through separable mechanisms. rs6849729, located in the densely tagged intronic region between rs6815001 and rs11942223, is among the candidate tag SNPs for these independent signals.

Practical Actions

Because rs6849729 sits 70 bp from rs6815001 and shares a nearly identical population frequency profile across ancestries, it most likely tags the same regulatory haplotype. T-allele carriers are likely exposed to the same modestly impaired renal urate clearance described for G-allele carriers at rs6815001. The SLC2A9 locus risk is consistently modifiable by diet: reducing dietary purines and fructose lowers the urate load on a transporter that is already working below optimal capacity.

Interactions

rs6849729 and rs6815001: These two intronic variants are 70 bp apart on chr4. Their almost identical ancestry-stratified allele frequencies (European ~42–43% C/T protective, East Asian ~9–11%, African ~67%) strongly indicate tight LD. Their clinical implications are therefore essentially identical; they should be considered redundant signals from the same haplotype block rather than independent compounding risk factors.

rs6849729 and rs3733591 (Arg265His): rs3733591 is a missense variant that directly reduces GLUT9 transport activity. It is statistically independent of the intronic signals in this region. Carrying a risk haplotype at rs6849729 (T allele) in addition to the Arg265His risk allele (C allele at rs3733591) compounds urate elevation from two distinct mechanisms — regulatory (expression/isoform balance) and functional (transport protein efficiency).

rs6849729 and ABCG2 rs2231142: ABCG2 handles intestinal urate secretion rather than renal reabsorption. Risk alleles at ABCG2 and SLC2A9 act through entirely separate pathways and their effects on serum urate are additive. Combined risk across both loci can push serum urate well above 7 mg/dL in otherwise healthy individuals.

Genotype Interpretations

What each possible genotype means for this variant.

CC Favorable Urate Clearance Normal

Favorable SLC2A9 haplotype — efficient urate clearance at this locus

You carry two copies of the C allele at rs6849729, the haplotype associated with more favorable renal urate handling at this intronic position in SLC2A9. About 19% of people globally share this genotype, though it is more common in people of African ancestry (~45%) and rare in East Asian populations (~1%). Your kidneys are not impaired by this particular SLC2A9 variant in their urate clearance capacity. Other factors — diet, body weight, alcohol, diuretic use, and other genetic variants at the SLC2A9 locus or ABCG2 — still influence your serum uric acid level.

CT Intermediate Urate Clearance Intermediate

One T risk allele — modestly impaired renal urate clearance from this SLC2A9 signal

rs6849729 sits 70 bp from the neighboring intronic SLC2A9 variant rs6815001 and shares a nearly identical ancestry-stratified frequency profile, indicating tight linkage disequilibrium. Both likely tag the same regulatory haplotype at the SLC2A9 4p16.1 locus, which has been shown by fine-mapping to contain at least five statistically independent effects on urate. The regulatory mechanism — rather than a missense change in the GLUT9 transporter itself — means the per-allele effect at this position is expected to be smaller than the missense variant rs3733591 (Arg265His), but it is additive with both rs3733591 and the ABCG2 rs2231142 intestinal secretion variant.

The sex-specific amplification seen across all SLC2A9 intronic signals applies here too: SLC2A9 intronic variants explain up to 6% of serum urate variance in women versus ~1.2% in men, with the difference mediated by estrogen's independent stimulation of renal urate excretion. CT carriers who are post-menopausal lose this hormonal buffer and may shift from well-compensated to clinically elevated urate.

TT Elevated Urate Risk High Risk

Two T risk alleles — elevated uric acid from this SLC2A9 intronic haplotype

rs6849729 is located in an intron of SLC2A9 at GRCh38 position chr4:9,957,108 — just 70 bp from the neighboring intronic variant rs6815001. Their near-identical allele frequency profiles across all major ancestry groups indicate tight linkage disequilibrium, with TT at rs6849729 and GG at rs6815001 residing on the same haplotype copies in most individuals. This haplotype is associated with impaired renal urate clearance through regulatory effects on GLUT9 expression or isoform balance, not a direct change to the transporter protein itself.

SLC2A9 intronic variants explain up to 6% of serum urate variance in women and ~1.2% in men, driven by estrogen's amplifying effect on renal urate excretion. TT carriers who are post-menopausal lose this hormonal buffer and can see serum uric acid rise into the hyperuricemia range (>6 mg/dL in women, >7 mg/dL in men) even without dietary provocation. The effect is further compounded in people who also carry risk alleles at rs3733591 (Arg265His missense — reduces transport efficiency) or ABCG2 rs2231142 (reduces intestinal urate secretion), since these three mechanisms act through distinct pathways and their effects are additive.

Metabolic syndrome amplifies SLC2A9 genetic risk: insulin resistance independently impairs renal urate excretion, and the combination of an unfavorable SLC2A9 haplotype with metabolic syndrome can push serum urate well above 7 mg/dL in healthy-seeming adults — before accounting for dietary purines or alcohol.